公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts | Ramalingam S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Jänne P.A. | Journal of Thoracic Oncology | 66 | 57 | |
2018 | Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer | Ramalingam S.S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A. | Journal of Clinical Oncology | 405 | 346 |